C ardiac hypertrophy, the compensatory response of the heart to stress, is characterized by nonmitotic growth, the addition of new sarcomeres, and fetal gene expression. 1 However, prolonged hypertrophy of the myocardium can progress to heart failure (HF), a leading cause of morbidity and mortality, often associated with sudden cardiac death.
increased mechanical load on the heart or through the action of neurohumoral mediators. 5 Numerous signaling pathways coordinate the cardiac hypertrophic response. Among them, the Ca 2+ /calmodulin-dependent phosphatase calcineurin is considered as a central prohypertrophic signaling effector in the myocardium. 6, 7 Activated calcineurin directly binds to and dephosphorylates the nuclear factor of activated T cells (NFAT) in the cytoplasm, permitting its translocation to the nucleus, where it participates in hypertrophic gene expression. 8 However, no single pathway seems to regulate cardiac hypertrophy alone. Rather, it appears more likely that each pathway operates as a component of an orchestrated hypertrophic network. For instance, the small G protein Ras, the stress-responsive mitogen-activated protein kinases, and the Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) can cross-talk with the calcineurin signaling pathway to regulate hypertrophic processes. [9] [10] [11] CaMKII is known to activate the myocyte enhancer factor 2 (MEF2) on class II histone deacetylases (HDAC) phosphorylation, thereby allowing this transcription factor to induce hypertrophic gene expression. 12, 13 In contrast to these growth-promoting pathways, several endogenous molecules in the heart have been shown to negatively regulate cardiac hypertrophy. [14] [15] [16] [17] [18] Increasing these negative signaling pathways may be of significant therapeutic value. In this context, Carabin (alias TBC/Rab GTPase activating protein [GAP] ), a protein expressed mainly in the immune system and the heart, raised our interest. 19 Carabin has 446 amino acid residues and contains 2 important regions, a putative Ras GTPase-activating protein (GAP) domain at its amino terminus and a carboxy-terminal domain that bears a calcineurin-interacting domain. 19, 20 Here, we provide the first evidence for an antihypertrophic role of Carabin in the heart. Using knockout mice for Carabin (Carabin −/− ), we showed a severely impaired cardiac function in response to pressure overloadinduced cardiac hypertrophy compared with control wild-type (WT) animals. Carabin was decreased in cardiac hypertrophy and failure. Compensation of its loss of expression using adeno-associated virus serotype 9 (AAV9)-mediated gene transfer in vivo protected the heart against hypertrophy and dysfunction. At the molecular level, Carabin repressed the prohypertrophic signaling of calcineurin, Ras/extracellular signal-regulated kinase (ERK), and CaMKII after cardiac pressure overload or adrenergic stimulation. Thus, this work establishes Carabin as a negative regulator of cardiomyocyte hypertrophy through the inhibition of various components of the intracellular signal-transduction network that coordinates hypertrophic responses.
Methods
The detailed and expanded methodology is provided in the onlineonly Data Supplement.
Animals
Mice carrying a global heterozygous knockout of Carabin were generated by targeted gene deletion as previously described by Schickel et al 21 (kindly provided by P.S.-S.). Eight-week-old male Carabin −/− mice and littermate controls (WT) used in this study were obtained by breeding Carabin +/− males and Carabin +/− females, both from a C57BL/6 genetic background. Mice were genotyped by polymerase chain reaction with the following 2 sets of primers as previously described 21 : 5′-GCAGCACAGCAGCTACAGGTCCC-3′/5′-CCCTCTGCAGACCTCATCCGCC-3′ and 5′-GCGCCACCAT TGCCCAGCTCTA-3′/5′-GCAGACCTCATCCGCCAGCGA G-3′. All mice used in this study were pathogen free and housed at constant (22°C) temperature on 12-hour light/dark cycles with ad libitum access to food and water.
AAV9 Production and Administration
AAV9-Carabin and AAV9-green fluorescent protein (GFP) were constructed and generated by Penn Vector Core (School of Medicine Gene Therapy Program, University of Pennsylvania). Physiological serum solution (100 μL) containing 3×10 11 genome copies per 1 mL AAV9 was injected in the retro-orbital sinus of 4-week-old male mice on a C57BL/6 genetic background (Janvier, France).
Adenoviral Infection
Bicistronic adenoviruses bearing human Carabin under the control of a cytomegalovirus promoter and GFP under internal ribosomal entry site were constructed and amplified by Genecust (Evry, France). One day after plating, cardiomyocytes were incubated for 2 hours with recombinant adenoviruses. After removal of the virus suspension, cells were replaced in maintenance medium for 2 days and then stimulated with the different drugs. Viruses were used at a multiplicity of infection of 10.
Statistical Analysis
Results are expressed as mean±SEM. Differences between groups have been analyzed by an unpaired Student t test and 2-way ANOVA followed by the Bonferroni posttest or Tukey posttest. Differences were considered significant at P<0.05, P<0.01 and P<0. 001 . Values of P<0.0001 were considered extremely significant. All statistical analyses were performed with GraphPad Prism (version 6.01).
Study Approval
All animal experiments were performed under European laws on the protection of animals of the University of Toulouse outlined in Council Directive 86/609/EEC. Mouse and rat experiments were approved and performed according to the guidelines of the Ethics and Animal Safety Committee of INSERM Toulouse/ENVT (agreement No. C3155507).
Results

Carabin Deficiency Potentiates the Progression of HF Under Hemodynamic Stress
To study the role of Carabin in the development of cardiac hypertrophy and HF, we first analyzed cardiac Carabin expression in mice and rats subjected to pressure overload induced by thoracic aortic constriction (TAC) and in failing human heart samples. In both rodent and human hearts, Carabin mRNA and protein amounts were markedly reduced compared with control hearts, suggesting that Carabin deficiency is associated with the development of cardiac hypertrophy and failure ( Figure 1A) .
Next, to test whether Carabin contributes to heart disease, we analyzed the hearts of Carabin −/− mice. This mouse line developed and reproduced normally, as previously described. 21 We found that Carabin was expressed in cardiac myocytes and not in cardiac fibroblasts isolated from the heart of WT animals ( Figure IA (Table 1 ) and the ratios of heart by guest on August 13, 2017 http://circ.ahajournals.org/ Downloaded from January 27, 2015 weight to tibia length and left ventricular weight to tibia length ( Figure 1B) were not different between WT and Carabindeficient mice. In addition, hearts from Carabin-deficient mice were macroscopically indistinguishable from those of WT animals ( Figure 1C ). However, 4 weeks after TAC, Carabin −/− mice showed a decline in cardiac contractility, as indicated by the reduced fractional shortening (Table 1) . Left ventricular end-diastolic and end-systolic internal diameters were largely increased in Carabin −/− mice after TAC (Table 1) , indicating LV dilatation. Notably, Carabin deficiency aggravated TAC-induced hypertrophic response compared with WT mice, as shown by increased ratios of heart weight to tibia length and left ventricular weight to tibia length and hematoxylin and eosin-stained heart sections ( Figure 1B and 1C) . These changes were accompanied by an increased cardiomyocyte cross-sectional area and induction of interstitial fibrosis ( Figure 1C ). In addition, the development of pulmonary congestion (ratio of lung weight to tibia length) as an indirect indicator of HF was also significantly increased in Carabin −/− mice ( Figure II in the online-only Data Supplement). Consistently, the expression of cardiac fetal genes (atrial natriuretic factor, brain natriuretic peptide, β-myosin heavy chain) and fibrotic markers (procollagen, type I, α1 and collagen type III) was Figure 1D ). Thus, Carabin deficiency does not cause baseline cardiac abnormalities but remarkably renders the heart more susceptible to stress-induced pathological cardiac remodeling.
Cardiotropic Expression of Carabin Prevents Cardiac Myocyte Hypertrophy and Preserves Cardiac Function After Pressure Overload
We first examined the effect of Carabin overexpression in isolated cardiac myocytes. We infected or transfected neonatal rat ventricular myocytes (NRVMs) with either a control vector or a vector encoding Carabin (Figure 2A and 2B) . Carabin-overexpressing cells had a dampened hypertrophic response to phenylephrine (10 μmol/L) treatment on the basis of analysis of cell surface area, sarcomeric organization, or the expression of the atrial natriuretic factor, which are hallmarks of cardiomyocyte hypertrophy (Figure 2A and 2B). Conversely, knockdown of Carabin with specific siRNA (Si-Carabin) further amplified the effect of phenylephrine on the expression of atrial natriuretic factor and cardiomyocyte surface area ( Figure III in the online-only Data Supplement). These results indicate an antihypertrophic effect of Carabin in cardiomyocytes.
Because Carabin was decreased in cardiac remodeling and HF, we tested whether its cardiac overexpression would prevent hypertrophy. For that, we chose a gene transfer approach using AAV9, which shows strong tropism for cardiac myocytes. 22 An AAV9 encoding Carabin or its control (GFP) was injected into the retro-orbital sinus of mice, and 5 weeks later, TAC was performed ( Figure IV in the online-only Data Supplement). Mice treated with AAV9-Carabin and subjected to TAC showed a level of cardiac Carabin similar to that observed in the basal condition ( Figure 2C ). Remarkably, restoration of Carabin expression with AAV9-Carabin significantly prevented cardiac hypertrophy, as judged by the ratios of heart weight to tibia length and left ventricular weight to tibia length ( Figure 2D ). Importantly, histological analysis showed a reduction in cardiomyocyte size and fibrosis in the TAC group treated with AAV9-Carabin ( Figure 2E ). In addition, upregulation of the hypertrophic gene markers and fibrotic markers was compromised in AAV9-Carabin ( Figure 2F ). This effect of Carabin was associated with a preserved cardiac function, as demonstrated by the echocardiographic data on left ventricular end-systolic internal diameter, left ventricular end-diastolic internal diameter, and fractional shortening ( Table 2 ). None of these effects occurred in the AAV9-GFP control group. These data strongly suggest that Carabin overexpression protects against the development of pathological cardiac hypertrophy.
Carabin Suppresses the Calcineurin/NFAT Signaling Pathway in a Ras-GAP-Independent Fashion
Next, we sought to determine the signaling mechanisms by which Carabin represses hypertrophy. Because Carabin contains a calcineurin-interacting domain, 19 we analyzed its ability to regulate calcineurin activity in NRVMs ( Figure 3A) . Cyclosporine A, a well-known inhibitor of calcineurin, was used as a positive control. Phenylephrine-induced calcineurin activation was significantly decreased in NRVMs infected with an adenovirus encoding Carabin (Ad.Carabin) compared with control cells (Ad.GFP; Figure 3A ), indicating that the phosphatase is a target of Carabin. Conversely, Si-Carabin potentiated phenylephrine-induced calcineurin activation and NFAT nuclear translocation ( Figure VA and VB in the online-only Data Supplement). In line with this result, phenylephrine and the calcium ionophore ionomycin failed to induce NFAT nuclear translocation in NRVMs transfected with Carabin ( Figure 3B and Figure VI in the online-only Data Supplement). Accordingly, the expression of the 1.4 isoform of the calcineurin-interacting protein (MCIP 1.4), a downstream effector for calcineurin-dependent activity 23, 24 that can serve as a highly sensitive readout for calcineurin activity in vivo, 14, 25 was prevented in left ventricular lysates of AAV9-Carabin-treated mice after TAC compared with control animals. In contrast, cardiac MCIP 1.4 expression was potentiated in Carabin −/− mice subjected to pressure overload ( Figure 3C ).
The interaction of Carabin with calcineurin/NFAT signaling was further confirmed by cotransfecting Si-Carabin and NFAT response elements coupled to the luciferase gene (NFAT-Luc) in NRVMs ( Figure 3D ). As expected, we observed a significant increase in phenylephrine-induced NFAT-Luc transcriptional activity in Si-Carabin-transfected cells compared with control siRNA stimulated with phenylephrine. A similar inhibitory effect of Si-Carabin on NFATLuc activity was observed under stimulation of a nonselective β-adrenergic receptor agonist, isoprenaline, indicating that Carabin inhibited NFAT activation in response not only to α-adrenergic receptor but also to β-adrenergic receptor activation ( Figure VII in the online-only Data Supplement). The presence of the C-terminal calcineurin-interacting domain in Carabin 19 raised the possibility that this domain might be involved in the regulation of calcineurin/NFAT signaling. Transient transfection experiments showed that indeed the inhibitory effect of Carabin on NFAT activity was dependent on its calcineurin-binding domain but independent of the Ras-GAP domain because mutations in the calcineurinbinding domain of Carabin (Carabin AAVGA mutant) or inactivation of the Carabin Ras-GAP domain (Carabin R141A mutant; Figure 3E ) abolished or mimicked the effect of Carabin, respectively ( Figure 3F ). Together, these data show that Carabin specifically inhibits the calcineurin/NFAT signaling pathway through its calcineurin-interacting domain and independently of its Ras-GAP activity.
Carabin Blocks Ras and ERK Activation Via Its Ras-GAP Domain
The fact that Carabin presents a Ras-GAP domain 19, 20 led us to investigate a potential Ras/Carabin interaction. Coimmunoprecipitation experiments, followed by immunoblotting, showed that Carabin interacted with Ras in NRVMs ( Figure 4A ). Knockdown of Carabin confirmed the specificity of this association ( Figure 4A ). The Ras/Carabin interaction was constitutive and was not influenced by adrenergic stimulation ( Figure 4A ). Consistent with its antihypertrophic action, Carabin decreased the amount of the active form of Ras that Ras-GTP produced under phenylephrine treatment, whereas Carabin R141A failed to inhibit Ras activation ( Figure 4B ). To further substantiate the inhibitory action of Carabin on Ras signaling, we analyzed its effect on the activation of a downstream target of Ras, the mitogen-activated protein kinase ERK. 26, 27 Si-Carabin enhanced phenylephrine-induced ERK activation by ≈70% ( Figure VIII in the online-only Data Supplement), whereas transfected Carabin decreased phosphorylated ERK in cardiac myocytes stimulated with phenylephrine compared with control cells ( Figure 4C ). Similarly, loss or gain of function of Carabin potentiated or prevented TAC-induced ERK activation in left ventricular homogenates, respectively ( Figure 4D and 4E). Of particular interest, phenylephrine-induced ERK was still observed in the presence of Carabin R141A , confirming the involvement of the Carabin Ras-GAP domain on the inhibition of the Ras/ERK pathway ( Figure 4F ). These data demonstrate that Carabin, via its interaction with Ras and 
Carabin Regulates HDAC4 Nucleocytoplasmic Shuttling
We previously showed that the small GTPase Ras regulates cardiac myocyte hypertrophy in coordination with CaMKII. 9, 28 Hence, to further analyze Carabin antihypertrophic signaling, we investigated its effect on CaMKII. Carabin prevented phenylephrine-or TAC-induced CaMKII autophosphorylation state (indicative of CaMKII activation), whereas CaMKII was activated more in heart samples of Carabin −/− mice subjected to TAC compared with WT animals ( Figures 5A-5C ). In contrast to Carabin and Carabin AAVGA , Carabin R141A failed to inhibit CaMKII activation, indicating that the effect of Carabin on CaMKII was Ras dependent ( Figure 5A ). Once phosphorylated by CaMKII, HDAC proteins are translocated out of the nucleus, thereby allowing MEF2 to activate its target genes. 13 Therefore, to ensure the relationship between Carabin and CaMKII hypertrophic signaling, we tested whether Carabin could influence HDAC4 nucleocytoplasmic shuttling and subsequent MEF2 transcriptional activation ( Figure 5D -5G). First, we examined HDAC4 nuclear export after TAC in Carabin −/− and AAV9-Carabin-treated mice. Although the myocardium of Carabin −/− mice showed an increase in the cytosolic/nuclear ratio of HDAC4 protein expression after TAC compared with WT mice (Figure 5D ), cardiac overexpression of Carabin prevented the nucleocytoplasmic shuttling of HDAC4 ( Figure 5E ). Second, we Next, to find out which domain of Carabin is important for its effect on HDAC4 and MEF2, we performed transient transfection in NRVMs using Carabin R141A and Carabin AAVGA mutants. KN93, a pharmacological inhibitor of CaMKII, was used as positive control. Both mutants failed to block HDAC4 translocation, suggesting that Carabin calcineurin-interacting and Ras-GAP domains are involved in HDAC4 nucleocytoplasmic shuttling ( Figure 5F ). In agreement with its effect on HDAC4, Carabin R141A did not prevent MEF2 activation in cells stimulated with phenylephrine ( Figure 5G ). We obtained an intermediate effect with Carabin AAVGA , suggesting that the calcineurin domain of Carabin is partially involved in the regulation of MEF2 transcriptional activity ( Figure 5G ). Taken together, these data show that, in response to adrenergic stimulation, Carabin, mainly through its Ras-GAP domain, prevents the activation of the prohypertrophic transcription factor MEF2 via the inhibition of CaMKII and HDAC nuclear export.
Both the Carabin Ras-GAP Domain and Calcineurin-Interacting Domain Are Involved in the Antihypertrophic Action of Carabin
Because Carabin regulates both calcineurin and Ras/CaMKII pathways, we assessed their relative contributions to the regulation of the cardiac myocyte hypertrophy of Carabin. Carabin R141A and Carabin AAVGA mutants were significantly less potent than the wild-type form of Carabin for inhibiting cell surface area, sarcomeric organization, or the atrial natriuretic factor promoter transcriptional activity (Figures X and XI in the online-only Data Supplement). The 2 Carabin mutants had a similar effect on cardiomyocyte hypertrophy markers. Transfection of Carabin R141A or Carabin AAVGA in the presence of either a pharmacological inhibitor of CaMKII, KN93, or calcineurin, cyclosporine A mimicked the effect of Carabin on phenylephrine-induced myocyte hypertrophy (Figures X and XI in the online-only Data Supplement). These data demonstrate that both the Carabin Ras-GAP domain and calcineurin-interacting domain are involved in the antihypertrophic action of Carabin. 
Discussion
This study is the first to show that Carabin is a negative regulator of cardiac hypertrophy under pathological conditions. This is supported by both gain-of-function and lossof-function studies. Because Carabin was downregulated in cardiac remodeling and failure, we sought to compensate for its loss through an in vivo gene transfer approach using AAV9-Carabin. Restoration of Carabin expression prevented the hypertrophic response to TAC and improved cardiac function, as evidenced by gravimetric, echocardiographic, fetal program, and cell size analysis. Consistent with the in vivo data, transfected Carabin inhibited phenylephrine-induced hypertrophy in NRVMs. Conversely, Si-Carabin potentiated cardiac hypertrophic markers. Importantly, Carabin-deficient mice developed a severe cardiac dysfunction in response to pressure overload, associated with altered contractile function, increased left ventricular dilation, and cardiac fibrosis. Furthermore, we observed severe HF with lung edema developed in Carabin-deficient mice after TAC. Together, these data suggest that Carabin plays a key role in the regulation of the transition from hypertrophy to HF in response to pathological stress.
Several endogenous repressors of cardiac hypertrophy have previously been identified. 18 Among them, Cabin 1,
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Calsarcin-1 14 and PICOT (protein kinase C-interacting cousing of thioredoxin) 16 have been shown to prevent pathological cardiac hypertrophy mainly through modulation of calcineurin activity. Although Carabin is another negative regulator of cardiac hypertrophy, this protein takes a special place among the others for 2 reasons. First, Carabin represents a promising target for preventing maladaptive cardiac hypertrophy. In contrast to other hypertrophic signaling molecules, Carabin does not seem to be required for normal development. Rather, Carabin gains functional importance during the cardiac stress response resulting from hypertrophic signaling and mechanical overload. This is supported by the absence of myocardial atrophy in Carabin-overexpressing mice and by data from Carabin-deficient mice that show no overt cardiac phenotype under basal conditions. Second, mechanistically, Carabin carries out a remarkable tripartite suppressive function. Indeed, Carabin exhibits inhibitory activity not only on calcineurin/NFAT (by its carboxy-terminal domain of interaction with calcineurin) and Ras/ERK (by its aminoterminus Ras-GAP domain) pathways but also on CaMKII and HDAC4 nuclear export.
Importantly, we noticed that Carabin is expressed in both the cytoplasm and nucleus of cardiac myocytes and induces the inhibition of these prohypertrophic signaling proteins, whatever the stimuli. Indeed, Carabin prevents NFAT transcriptional activity under α1-or β-adrenergic receptor stimulation. Expression of the gene encoding MCIP1.4, which is under tight control by calcineurin activity, 30 was further augmented or decreased in hearts of Carabin −/− or AAV9-Carabininjected mice on pressure overload, respectively. Likewise, the effect of Carabin on CaMKII activity was observed in vivo in the TAC model and in NRVMs treated with either phenylephrine or 8-pCPT ( Figure XIIA in the online-only Data Supplement), an exchange protein directly activated by cAMP-selective agonist, which is a potent activator of cAMPdependent cardiomyocyte hypertrophy. 26, 31 Phosphorylation of the sarcoplasmic ryanodine receptor, which is another effector of CaMKII, was inhibited by Carabin after activation of the prohypertrophic factor exchange protein directly activated by cAMP ( Figure XIIB in the online-only Data Supplement). Together, these data suggest that Carabin does not belong to a protein complex specifically associated with a subcellular compartment or a signaling pathway but most probably exerts its functions in concert with various proteins localized in distinct intracellular compartments.
Because Carabin expression was decreased in human failing heart and in TAC-induced hypertrophy in rodents, we speculate that this downregulation of Carabin may play an active role in promoting cardiac hypertrophy under stress conditions. In support of this hypothesis, Carabin overexpression attenuated hypertrophic signaling and protected the heart against hypertrophic remodeling. Cardiac gene therapy has emerged as a promising approach for treating HF, supported by a growing number of positive preclinical studies 32 and a recent successful result in phase II study (the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease [CUPID] trial) targeting the cardiac sarcoplasmic/ endoplasmic reticulum Ca 2+ ATPase pump. 33 Our findings that restoration of Carabin expression with AAV9-Carabin improves cardiac function in mice with HF suggest that Carabin gene transfer may provide a novel therapeutic strategy for the treatment of HF. As a next step, it will be important to test the beneficial impact of Carabin gene transfer in a preclinical study using a large-animal model of HF.
Although our data obtained both in vitro and in vivo support a cardioprotective role of Carabin, we found a 50% increase in the expression of Carabin in response to 1 day of treatment with phenylephrine in vitro ( Figure IIIB in the online-only Data Supplement). Accordingly, the proximal promoter region of Carabin revealed the presence of multiple consensus NFAT-binding sites, 19 suggesting that the expression of Carabin might be regulated by the calcineurin signaling pathway. Therefore, one can imagine a scenario in which the upregulation of Carabin at the early phase of hypertrophy development may counteract the progression of pathological cardiac growth, and when the stress persists as observed 4 weeks after TAC, Carabin may be degraded, thereby contributing to disease progression. However, to validate this hypothesis, further experiments are required to show the upregulation of Carabin at the early phase of pressure overload-induced cardiac hypertrophy. Interestingly, bioinformatic analysis of the Carabin sequence showed many potential phosphorylation sites, mainly for protein kinase A and C (analysis with NetPhosK, Expasy software), which are implicated in cardiac hypertrophy signaling, 5 suggesting that Carabin may be tightly regulated by phosphorylation and dephosphorylation, which can then influence its proteolytic degradation.
Calcineurin, CaMKII, and Ras signaling pathways may converge at the same downstream effectors such as the transcriptional factors NFAT and MEF2 to regulate cardiac growth. For instance, studies in transgenic mice showed that inhibition of MEF2 abrogated the effects of calcineurin on cardiac dilation and dysfunction, suggesting that this transcription factor was a target of calcineurin. 34 Yet, Li and collaborators 35 reported that calcineurin regulates MEF2 transcriptional activity in C2C12 myoblasts. In contrast, CaMKII is also known to negatively regulate calcineurin/NFAT signaling by phosphorylation. 11 These different signaling pathways are therefore tightly linked, and our finding on Carabin adds complexity to this cross-talk.
As expected, mutations in the calcineurin-binding domain of Carabin (Carabin AAVGA ) prevent NFAT activation. These data, combined with the observation that NFAT transcriptional activity was unaffected by the Carabin R141A mutant, indicate that Carabin inhibits calcineurin/NFAT signaling pathways only via its calcineurin-binding domain and in a Ras-independent fashion. On the contrary, the inhibitory effect of Carabin on CaMKII involves its Ras-GAP function because Carabin R141A fails to prevent HDAC4 nuclear translocation and subsequent MEF2 transcriptional activation. This finding is in agreement with a previous report showing that increased MEF2 activity in response to hypertrophic stimuli was dependent on Ras. 10 The calcineurin-binding domain of Carabin is also involved in the inhibitory effect of Carabin on the CaMKII pathway because the mutant Carabin AAVGA behaves as the vector control on HDAC4 nucleocytoplasmic shuttling. The fact that Carabin AAVGA had a slight tendency to inhibit MEF2 activation could be explained by a differential interaction between calcineurin/HDAC4 and calcineurin/MEF2. This hypothesis is strengthened by the study of Grégoire and collaborators, 36 who showed that calcineurin interacted with HDAC4 more strongly than MEF2.
Finally, we found that the antihypertrophic action of Carabin was dependent on its Ras-GAP domain and calcineurin-interacting domain. This makes sense for 2 reasons: The Ras-GAP domain of Carabin prevents the activation of Ras/ CaMKII and the calcineurin-interacting domain of Carabin specifically inhibits calcineurin/NFAT signaling, and both Ras/CaMKII signaling and calcineurin signaling are involved in cardiac hypertrophy. 5 Our finding that the calcineurin-binding domain of Carabin is implicated in the inhibitory effect of Carabin on HDAC translocation and MEF2 activation may justify why Carabin AAVGA is less potent than KN93 in inhibiting phenylephrine-induced cardiomyocyte hypertrophy.
This cooperation between the Carabin Ras-GAP domain and calcineurin-interacting domain to exert their inhibitory action on hypertrophy may explain why Carabin R141A is less effective than cyclosporine A in preventing cardiomyocyte hypertrophy.
Conclusions
Our study has revealed Carabin as a novel and negative regulatory point for modulating calcineurin/NFAT, Ras/ERK, and CaMKII signaling. Hypertrophic remodeling of the heart under chronic stress appears to result, at least in part, from downregulation of Carabin and thus from insufficient control by this protein.
Our finding that Carabin has a protective function in the heart in response to hemodynamic stress suggests that Carabin may be a potential diagnostic and therapeutic target for heart disease. 
CLINICAL PERSPECTIVE
Prolonged hypertrophy of the myocardium can progress to heart failure, a leading cause of morbidity and mortality, often associated with sudden cardiac death. Understanding the underlying molecular and cellular mechanisms of cardiac hypertrophy is crucial for developing new therapeutic strategies. Among the numerous signaling pathways that coordinate the cardiac hypertrophic response, the Ca 2+ /calmodulin-dependent phosphatase calcineurin, the small G protein Ras, and the Ca 2+ / calmodulin-dependent protein kinase II are considered central prohypertrophic signaling effectors in the myocardium. Here, we characterized Carabin, a protein expressed in cardiomyocytes that functions as an endogenous inhibitor of calcineurin, Ras, and Ca 2+ /calmodulin-dependent protein kinase II prohypertrophic signaling. Carabin-deficient mice developed a severe cardiac dysfunction in response to myocardial pressure overload, associated with altered contractile function, increased hypertrophic markers, and cardiac fibrosis. Interestingly, Carabin was downregulated both in animal models of cardiac hypertrophy and in human failing myocardium. Compensation for Carabin downregulation in a cardiac disease model using viral gene transfer in vivo protected the heart against hypertrophy and dysfunction. Together, these data indicate that Carabin acts as a negative regulator of pathological cardiac hypertrophy through the inhibition of various components of the intracellular signal-transduction network that coordinates hypertrophic responses. We believe that Carabin gene transfer may provide a novel therapeutic strategy for the treatment of heart failure.
SUPPLEMENTAL MATERIAL Expanded Methods
Reagents
Phenylephrine (PE), Isoprenaline (Iso) and cyclosporin A (CsA), ionomycin and KN93 were obtained from Sigma-Aldrich. The non-hydrolysable Epac agonist, Sp-8-(4-chlorophenylthio)-2′-O-methyl-cAMP (8-pCPT) was from BioLog.
Human heart tissues
All studies are conformed to the Declaration of Helsinki and institutional ethical regulations.
Human failing hearts samples were a kind gift from Dr J.L Samuel (Lariboisiere Hospital, France).
Explanted failing hearts were obtained from patients undergoing cardiac transplantation for end-stage cardiac HF secondary to idiopathic dilated cardiomyopathy. All patients had New York Heart Association (NYHA) Class IV HF, with a mean pretransplant left ventricular ejection fraction of 22±4 %. None had received chronic intravenous inotropic support over at least 7 days immediately prior to transplantation. Heart failure therapy consisted of angiotensin converting enzyme inhibitors and diuretics in all patients. Non-failing hearts were obtained from prospective multiorgan donors who had died from head trauma or intracranial bleeds; these hearts were unsuitable for transplantation for technical reasons. All tissues were stored at -80 o C until further analyses.
Cell Culture
All procedures for cardiac myocyte isolation were performed in accordance with the Guide for the care and use of laboratory animals and the veterinary committee has been informed of the myocyte isolation protocol used. Neonatal rat ventricular myocytes, mouse and rat adult cardiac myocytes, and cardiac fibroblasts were isolated as previously described by Wollert et al. 1 , and Verde et al. 2 , respectively. All media, sera and antibiotics used in cell culture were purchased from Invitrogen (Cergy Pontoise, France).
Plasmid construct, siRNA and transfection
The plasmid constructs were generously provided by the following: Carabin by Dr J.O Liu GUGGACCCUGUAGAUGGCGTT-3') were purchased from Ambion.
Thoracic aortic constriction and echocardiographic assessment
Thoracic aortic constriction (TAC) was performed on mice anesthetized with 1% isofluorane.
After endotracheal intubation, mice were connected to a rodent ventilator. The transverse aorta was isolated and TAC was performed by tying a nylon suture ligature against a 26-gauge needle, the latter being promptly removed to induce pressure overload cardiac hypertrophy. After aortic constriction, the chest was closed, the pneumothorax was evacuated, and the mice were extubated and allowed to recover from the anesthesia. Sham operated animals underwent the same operation except for aortic constriction. Echocardiography was carried out on lightly anesthetized (1% isoflurane in air) mice placed on a heating pad. The left ventricle dimensions were obtained during TM mode acquisition from the parasternal short axis view at the level of the papillary muscles using a Vivid7 echograph and a 14 MHz transducer (i3L, GEHealthcare). Images were transferred and analyzed off line with EchoPAC (GEHealthcare). Echocardiographies were performed with protocols blinded with respect to genotype. TAC was performed in rats as previously described 3 .
Total RNA isolation and real-time quantitative RT-PCR
Extraction of RNA from left ventricles was performed using a QIAGEN RNeasy Mini Kit (Qiagen), as described by the manufacturer. cDNA was synthesized using the iScript Real-Time PCR System (Applied Biosystems). PCR reactions were performed in triplicates.
Results were expressed as the average of relative gene expression normalized for mouse RPL32 mRNA and human GAPDH expressions for each sample and the ∆∆CT method was used for data analysis. 
RPL32
Rpl32
Forward GCTGCTGATGTGCAACAAA Mouse Reverse GGGATTGGTGACTCTGATGG ANF, atrial natriuretic factor; BNP, brain natriuretic peptide; Col1A1, pro-collagen, type I, alpha 1; Carabin; Col3, collagen type 3; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GBA, glucocerebrosidase; MCIP 1.4, modulatory calcineurin-interaction protein 1.4; β-MHC, beta-myosin heavy-chains; RPL32, ribosomal protein L32. 
Immunoprecipitation and western blot
HDAC translocation
Neonatal rat cardiac myocytes were collected and harvested in ice cold PBS. After centrifugation at 5000 rpm for 2 min, cells were lysed on ice (15 min) in a hypotonic buffer 
Ras activation assay
Ras pull-down experiments were performed using a GST fusion protein containing the Ras Binding Domain of Raf1 as previously described 4 .
Calcineurin assay
Calcineurin phosphatase activity was measured on cell extracts using the calbiochem 
Determination of fibrosis
Hearts were transversely sectioned at 10 µm thickness, fixed with 4% paraformaladehyde and stained with Masson's Trichrome. Slides were scanned with NanoZoomer (Hamamatsu v1. 2) and fibrosis was measured as positively stained area with Masson's Trichrome and expressed as percent of total area, using ImageJ software (RSB).
Hematoxylin and eosin-staining
Hearts were collected, fixed in 4% paraformaldehyde, dehydrated, and embedded in OCT tissue embedding compound (Tissue Tek, EMS). Longitudinal sections were performed at 10 μm in thickness and stained with hematoxylin and eosin for histological examination. 
